FIG. 7.

rSV5 infection of BALB/c BMDC does not prevent LPS-induced maturation of BMDC. BALB/c BMDC were LPS treated, mock infected, rSV5 infected, or treated with combinations of LPS (200 ng/ml) and rSV5 (MOI = 10). LPS and rSV5 were added concurrently to BMDC for 24 h, or LPS was added 24 h following infection with rSV5. The graph shows the geometric mean fluorescence intensity of CD80 for CD11c⁺ cells for BALB/c BMDC. The graphs show the average ± standard error of the mean of three independent experiments. P values were calculated using the paired t test. *, upregulation of CD80 on BALB/c BMDC treated with LPS and rSV5 (P = 0.009) and rSV5 for 24 h followed by LPS (P = 0.003) was statistically significant relative to that of rSV5-infected BMDC.